A Phase 1 Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of VSA003 in Chinese Adult Healthy Volunteers
Latest Information Update: 15 May 2023
At a glance
- Drugs Zodasiran (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia; Hypertriglyceridaemia
- Focus Adverse reactions
- Sponsors Visirna Therapeutics
- 15 May 2023 New trial record